Loading
AB
Akoya Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Sept 2023.
Akoya Biosciences, Inc.: what insiders have been doing
Akoya Biosciences, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Akoya Biosciences, Inc. has had no insider filing for more than a year; the last one goes back to 10 July 2025.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€2M
10 ops. · all time
Sell Volume
€2M
13 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$70.3M
Gross profitUS$41.2M59% margin
Net income-US$47.7M-67.8% margin
Last declaration on 10 July 2025
Declarations90 total
20,000 sharesCommon StockSEC:0001062993-25-012722:0
984,513 sharesCommon StockSEC:0001062993-25-012726:0
234,592 sharesCommon StockSEC:0001062993-25-012723:0
54,452 sharesCommon StockSEC:0001062993-25-012728:0
9,488 sharesCommon StockSEC:0001062993-25-012727:0
28,500 sharesCommon StockSEC:0001062993-25-012732:0
62,566 sharesCommon StockSEC:0001062993-25-012731:0
393,338 sharesCommon StockSEC:0001062993-25-012730:0
16,772 sharesCommon StockSEC:0001062993-25-012729:0
670 shares@ US$1.2526.8% of flowCommon StockSEC:0001062993-25-010697:0
16,432 shares@ US$1.3511.4% of flowCommon StockSEC:0001062993-25-006998:0
7,550 shares@ US$1.706.2% of flowCommon StockSEC:0001062993-25-006291:0
2,310 shares@ US$1.702.9% of flowCommon StockSEC:0001062993-25-006290:0
3,594 shares@ US$1.633.1% of flowCommon StockSEC:0001062993-25-004359:0
1,283 shares@ US$1.63100.0% of flowCommon StockSEC:0001062993-25-004357:0
2,310 shares@ US$1.632.9% of flowCommon StockSEC:0001062993-25-004352:0
7,550 shares@ US$1.636.2% of flowCommon StockSEC:0001062993-25-004348:0
3,851 shares@ US$1.63100.0% of flowCommon StockSEC:0001062993-25-004368:0
87,500 shares0Common StockSEC:0001062993-24-019524:0
87,500 shares0Common StockSEC:0001062993-24-019520:0
87,500 shares0Common StockSEC:0001062993-24-019525:0
218,750 shares0Common StockSEC:0001062993-24-019518:0
87,500 shares0Common StockSEC:0001062993-24-019522:0
40,000 shares0Common StockSEC:0001062993-24-016035:0
7,500 shares@ US$0.3031.1% of flowCommon StockSEC:0001104659-24-070825:0
25 of 90 declarations
About Akoya Biosciences, Inc.
Akoya Biosciences, Inc. (NASDAQ: AKYA) is a United States-based life sciences company listed on the NASDAQ market. It is focused on spatial biology, a segment of the tools and diagnostics industry that helps researchers analyze tissue while preserving cellular context. This is especially relevant in oncology, immunology, neuroscience, and biomarker discovery, where the location of proteins and cells within tissue can be as important as the biology itself. The company is headquartered in Marlborough, Massachusetts, in the Boston life-science corridor, and it grew out of the Phenoptics/spatial imaging platform business before becoming an independent company in the mid-2010s.
Akoya’s business model centers on instruments, reagents, multiplex panels, software-enabled workflows, and biopharma services. Its core platforms include PhenoImager and PhenoCycler-Fusion, alongside assay and panel families such as PhenoCode. These products are designed for high-plex tissue imaging and single-cell spatial proteomics, enabling academic labs, translational research centers, contract research organizations, and pharmaceutical companies to generate more actionable tissue-level data. In competitive terms, Akoya occupies a niche but strategically attractive position in the rapidly developing spatial omics market. Its differentiation lies in its specialized technology stack, its focus on high-plex workflows, and its expanding set of applications across drug discovery, biomarker validation, and companion diagnostic development.
Read moreShow less
Geographically, the company serves customers across North America, Europe, and Asia-Pacific, reflecting the global adoption of spatial biology tools in both research and biopharma pipelines. Akoya’s stated mission is to bring context to biology and human health through spatial phenotyping, which captures the company’s role as an enabling platform rather than a traditional therapeutics business. For investors, the model is notable because it combines capital equipment, recurring reagent sales, and service revenue opportunities, which can support longer-term commercial relationships if adoption continues to broaden.
Recent developments have been important. In 2025, Akoya expanded its biopharma portfolio with a new assay aimed at antibody-drug conjugate development in breast cancer, and it announced, together with Enable Medicine, the launch of the largest commercially available single-cell spatial proteomics atlas. Another major strategic event in 2025 was the announced merger agreement with Quanterix, highlighting that Akoya is in a period of corporate transition and strategic repositioning. Overall, Akoya Biosciences is a U.S. NASDAQ-listed precision medicine tools company whose outlook is tied to the growth of spatial biology, broader adoption of multiplex tissue analysis, and successful execution of its commercial and strategic roadmap.
